Acute Demyelinating Events Following Vaccines: A Case-Centered Analysis

被引:46
作者
Baxter, Roger [1 ]
Lewis, Edwin [1 ]
Goddard, Kristin [1 ]
Fireman, Bruce [1 ]
Bakshi, Nandini [2 ]
DeStefano, Frank [3 ]
Gee, Julianne [3 ]
Tseng, Hung Fu [4 ]
Naleway, Allison L. [5 ]
Klein, Nicola P. [1 ]
机构
[1] Northern Calif Kaiser Permanente Vaccine Study Ct, Oakland, CA USA
[2] Permanente Med Grp Inc, Antioch, CA USA
[3] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA
[4] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA
[5] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA
关键词
vaccine; immunization; transverse myelitis; acute disseminated encephalomyelitis; INFLUENZA VACCINATION; TRANSVERSE MYELITIS; OPTIC NEURITIS; HEPATITIS-B; RISK; IMMUNIZATION; DISEASES; AUTOIMMUNITY; CHILDHOOD; ADULTS;
D O I
10.1093/cid/ciw607
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Case reports have suggested that vaccines may trigger transverse myelitis (TM) or acute disseminated encephalomyelitis (ADEM), but the evidence for a causal association is inconclusive. We analyzed the association of immunization and subsequent development of TM or ADEM. Methods. We identified all cases of TM and ADEM in the Vaccine Safety Datalink population. Using a case-centered method, we compared vaccination of each case to vaccination of all matched persons in the study population, who received the same type of vaccine, with respect to whether or not their vaccination occurred during a predetermined exposure interval. We calculated a risk difference (excess risk) of TM and ADEM for each vaccine. Results. Following nearly 64 million vaccine doses, only 7 cases of TM and 8 cases of ADEM were vaccinated during the primary exposure window 5-28 days prior to onset. For TM, there was no statistically significant increased risk of immunization. For ADEM, there was no statistically significant increased risk following any vaccine except for Tdap (adolescent and adult tetanus, reduced diphtheria, acellular pertussis) vaccine. Based on 2 exposed cases, the odds ratio for Tdap exposure 5-28 days prior to ADEM onset was 15.8 (95% confidence interval [CI], 1.2-471.6; P = .04), and the estimated excess risk was 0.385 (95% CI, -.04 to 1.16) cases per million doses. Conclusions. We found no association between TM and prior immunization. There was a possible association of ADEM with Tdap vaccine, but the excess risk is not likely to be more than 1.16 cases of ADEM per million vaccines administered.
引用
收藏
页码:1456 / 1462
页数:7
相关论文
共 32 条
[11]   Vaccinations and risk of central nervous system demyelinating diseases in adults [J].
DeStefano, F ;
Verstraeten, T ;
Jackson, LA ;
Okoro, CA ;
Benson, P ;
Black, SB ;
Shinefield, HR ;
Mullooly, JP ;
Likosky, W ;
Chen, RT .
ARCHIVES OF NEUROLOGY, 2003, 60 (04) :504-509
[12]  
DeStefano Frank, 2002, Expert Rev Vaccines, V1, P461, DOI 10.1586/14760584.1.4.461
[13]   NEUROLOGICAL COMPLICATIONS OF IMMUNIZATION [J].
FENICHEL, GM .
ANNALS OF NEUROLOGY, 1982, 12 (02) :119-128
[14]   Influenza Vaccination and Mortality: Differentiating Vaccine Effects From Bias [J].
Fireman, Bruce ;
Lee, Janelle ;
Lewis, Ned ;
Bembom, Oliver ;
van der Laan, Mark ;
Baxter, Roger .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2009, 170 (05) :650-656
[15]   Transverse Myelitis [J].
Frohman, Elliot M. ;
Wingerchuk, Dean M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (06) :564-572
[16]   DIFFUSE MYELITIS ASSOCIATED WITH RUBELLA VACCINATION [J].
HOLT, S ;
HUDGINS, D ;
KRISHNAN, KR ;
CRITCHLEY, EMR .
BRITISH MEDICAL JOURNAL, 1976, 2 (6043) :1037-1038
[17]   Post-vaccination encephalomyelitis: Literature review and illustrative case [J].
Huynh, William ;
Cordato, Dennis J. ;
Kehdi, Elias ;
Masters, Lynette T. ;
Dedousis, Chris .
JOURNAL OF CLINICAL NEUROSCIENCE, 2008, 15 (12) :1315-1322
[18]  
Kawasaki A, 1998, J NEURO-OPHTHALMOL, V18, P56
[19]   A new and improved confidence interval for the Mantel-Haenszel risk difference [J].
Klingenberg, Bernhard .
STATISTICS IN MEDICINE, 2014, 33 (17) :2968-2983
[20]  
Knebusch M, 1998, DEV MED CHILD NEUROL, V40, P631